person · Reporting owner

Barrett Elizabeth A.

Disclosed activity across 4 companies

Tapewire entity: 35887
SEC CIK: 0001764157

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allogene Therapeutics, Inc.ALLO · Entity 5243	Director	June 18, 2026	June 23, 2026
Science 37 Holdings, Inc.LSAQ · Entity 15235	Director	November 20, 2020	November 20, 2020
UroGen Pharma Ltd.URGN · Entity 4466	Chief Executive Officer	January 31, 2026	February 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allogene Therapeutics, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	95,400	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 95,400 · Balance 95,400 F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.

Science 37 Holdings, Inc.

Report date November 20, 2020 · Filed November 20, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,000	Reported balance Holding disclosure · report date 2020-11-20 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 6,000

UroGen Pharma Ltd.

Report date January 31, 2026 · Filed February 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	153,195	Reported balance After 2026-01-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-31 · Grant · Acquired 153,195 · Balance 153,195 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Sage Therapeutics, Inc.

Report date July 31, 2025 · Filed July 31, 2025

Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-07-31 transaction · row 1 1 source row Row 1 · 2025-07-31 · Other · Disposed 3,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2034-06-10	Direct	0	Reported balance After 2025-07-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.

F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 18, 2026 Filed Jun 23, 2026 20:26 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantRestricted Stock Unit · Derivative	95,400	$0.00	$0.00	Disclosure SEC source: 0001764157-26-000004 · wk-form4_1782246402.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,400 Underlying: Common Stock · 95,400 shares Expires not disclosed F1 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company. F1 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company. F1 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company. Read SEC document
January 31, 2026 Filed Feb 19, 2026 15:46 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Units · Derivative	153,195	$0.00	$0.00	Disclosure SEC source: 0001437749-26-004638 · rdgdoc.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,195 Underlying: Ordinary Shares · 153,195 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. F2 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. Read SEC document
July 31, 2025 Filed Jul 31, 2025 11:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Disposition to issuerStock Option (Right to Buy) · Derivative	21,500	Not disclosed Strike: $6.77	Not disclosed	Disclosure SEC source: 0000950170-25-100675 · ownership.xml · derivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,500 shares Expires 2034-06-10 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. Read SEC document
July 31, 2025 Filed Jul 31, 2025 11:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	OtherCommon Stock	3,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-100675 · ownership.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2 · kind: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2 · price: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. Read SEC document
July 28, 2025 Filed Jul 30, 2025 20:08 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantPerformance Stock Units · Derivative	87,615	$0.00	$0.00	Disclosure SEC source: 0001437749-25-023969 · rdgdoc.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,615 Underlying: Ordinary Shares · 87,615 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: Represents performance stock units ("PSUs") granted to the reporting person on January 31, 2024 that were earned upon the achievement of a corporate milestone event. These PSUs remain subject to continued service through December 31, 2025, at which time they will vest and settle in ordinary shares. F2 · derivative.expiration_date: Represents performance stock units ("PSUs") granted to the reporting person on January 31, 2024 that were earned upon the achievement of a corporate milestone event. These PSUs remain subject to continued service through December 31, 2025, at which time they will vest and settle in ordinary shares. Read SEC document
June 18, 2025 Filed Jun 24, 2025 01:03 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantRestricted Stock Unit · Derivative	95,400	$0.00	$0.00	Disclosure SEC source: 0001737287-25-000074 · wk-form4_1750727007.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,400 Underlying: Common Stock · 95,400 shares Expires not disclosed F1 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company. F1 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company. F1 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company. Read SEC document
June 11, 2025 Filed Jun 13, 2025 16:13 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	21,500	$0.00 Strike: $6.77	$0.00	Disclosure SEC source: 0001562180-25-004787 · primarydocument.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2035-06-11 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 11, 2026 or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
January 31, 2025 Filed Feb 4, 2025 16:49 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Units · Derivative	96,377	$0.00	$0.00	Disclosure SEC source: 0001437749-25-002683 · rdgdoc.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,377 Underlying: Ordinary Shares · 96,377 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028. F2 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028. Read SEC document
June 05, 2024 Filed Jun 7, 2024 21:34 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to buy) · Derivative	191,082	$0.00 Strike: $2.44	$0.00	Disclosure SEC source: 0001593968-24-000840 · primary_01.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,082 Underlying: Common Stock · 191,082 shares Expires 2034-06-05 F1 · derivative.exercise_date: Vesting in 12 equal monthly installments Read SEC document
January 31, 2024 Filed Feb 3, 2024 00:04 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Units · Derivative	87,615	$0.00	$0.00	Disclosure SEC source: 0001437749-24-003012 · rdgdoc.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,615 Underlying: Ordinary Shares · 87,615 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027. F2 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027. Read SEC document
June 13, 2023 Filed Jun 15, 2023 21:03 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to Buy) · Derivative	116,120	$0.00 Strike: $5.70	$0.00	Disclosure SEC source: 0001593968-23-001012 · primary_01.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,120 Underlying: Common Stock · 116,120 shares Expires 2033-06-13 F1 · derivative.exercise_date: Vesting in 12 equal monthly installments Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:40 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantPerformance Stock Units · Derivative	100,000	$0.00	$0.00	Disclosure SEC source: 0001437749-23-002358 · rdgdoc.xml · derivative · entry 7 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires not disclosed F6 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one ordinary share of the Issuer. F8 · date: The performance stock units were approved by the Board of Directors of the Issuer on January 31, 2023. If the performance stock units are not ratified by the Issuer's shareholders at the Issuer's 2023 annual general meeting, the performance stock units will terminate. F7 · derivative.exercise_date: All shares underlying the performance stock units will vest upon achievement of a corporate milestone event. F7 · derivative.expiration_date: All shares underlying the performance stock units will vest upon achievement of a corporate milestone event. Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:40 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantEmployee Stock Option (right to buy) · Derivative	125,000	$0.00 Strike: $10.39	$0.00	Disclosure SEC source: 0001437749-23-002358 · rdgdoc.xml · derivative · entry 6 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Ordinary Shares · 125,000 shares Expires 2033-01-31 F5 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:40 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Units · Derivative	75,000	$0.00	$0.00	Disclosure SEC source: 0001437749-23-002358 · rdgdoc.xml · derivative · entry 5 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Ordinary Shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. F4 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:40 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	13,333	$0.00	$0.00	Disclosure SEC source: 0001437749-23-002358 · rdgdoc.xml · derivative · entry 4 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Ordinary Shares · 13,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2021 representing 40,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2022. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2021 representing 40,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2022. Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:40 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001437749-23-002358 · rdgdoc.xml · derivative · entry 3 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 15,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2021. F2 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 15,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2021. Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:40 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	13,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-002358 · rdgdoc.xml · nonDerivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:40 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-002358 · rdgdoc.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
June 15, 2022 Filed Jun 17, 2022 20:57 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to Buy) · Derivative	71,070	$0.00 Strike: $9.62	$0.00	Disclosure SEC source: 0001214659-22-008168 · marketforms-56493.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,070 Underlying: Common Stock · 71,070 shares Expires 2032-06-15 F1 · derivative.exercise_date: Vesting in 12 equal monthly installments. Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:32 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right to buy) · Derivative	150,000	$0.00 Strike: $7.72	$0.00	Disclosure SEC source: 0001209191-22-006383 · doc4.xml · derivative · entry 7 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 150,000 shares Expires 2032-01-31 F5 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025 Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:32 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	13,333	$0.00	$0.00	Disclosure SEC source: 0001209191-22-006383 · doc4.xml · derivative · entry 6 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Underlying: Ordinary Shares · 13,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F4 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2021 representing 40,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2022. F4 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2021 representing 40,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2022. Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:32 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-006383 · doc4.xml · derivative · entry 5 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 15,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2021. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 15,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2021. Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:32 UTC	UroGen Pharma Ltd. URGN · Entity 4466	SaleOrdinary Shares	5,960	$7.58	$45,176.80	Disclosure SEC source: 0001209191-22-006383 · doc4.xml · nonDerivative · entry 4 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,358 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:32 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	13,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-006383 · doc4.xml · nonDerivative · entry 3 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:32 UTC	UroGen Pharma Ltd. URGN · Entity 4466	SaleOrdinary Shares	2,235	$7.58	$16,941.30	Disclosure SEC source: 0001209191-22-006383 · doc4.xml · nonDerivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,985 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:32 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-006383 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
January 04, 2022 Filed Jan 7, 2022 13:38 UTC	UroGen Pharma Ltd. URGN · Entity 4466	SaleOrdinary Shares	46,968	$9.15	$429,757.20	Disclosure SEC source: 0001209191-22-002305 · doc4.xml · nonDerivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,220 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document
January 03, 2022 Filed Jan 7, 2022 13:38 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	105,689	$0.00	$0.00	Disclosure SEC source: 0001209191-22-002305 · doc4.xml · derivative · entry 3 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 105,689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted RSUs on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. 33.33% of the RSUs vested in equal monthly installments through January 3, 2021. The remaining 33.33% of the RSUs vested on January 3, 2022. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. 33.33% of the RSUs vested in equal monthly installments through January 3, 2021. The remaining 33.33% of the RSUs vested on January 3, 2022. Read SEC document
January 03, 2022 Filed Jan 7, 2022 13:38 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	105,689	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-002305 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
July 30, 2021 Filed Aug 3, 2021 21:32 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to Buy) · Derivative	63,385	$0.00 Strike: $21.95	$0.00	Disclosure SEC source: 0001214659-21-008123 · marketforms-53498.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,385 Underlying: Common Stock · 63,385 shares Expires 2031-07-30 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in a series of 36 successive equal monthly installments measured from the date of grant. Read SEC document
May 19, 2021 Filed May 21, 2021 17:44 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Tax withholdingOrdinary Shares	1,240	$17.51	$21,711.04	Disclosure SEC source: 0001209191-21-034823 · doc4.xml · nonDerivative · entry 4 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,499 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of RSUs. Read SEC document
May 19, 2021 Filed May 21, 2021 17:44 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Tax withholdingOrdinary Shares	2,185	$17.51	$38,256.95	Disclosure SEC source: 0001209191-21-034823 · doc4.xml · nonDerivative · entry 3 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,739 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of RSUs. Read SEC document
January 31, 2021 Filed Feb 2, 2021 19:54 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Units · Derivative	40,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-006700 · doc4.xml · derivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Ordinary Shares · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024 F3 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024 Read SEC document
January 31, 2021 Filed Feb 2, 2021 19:54 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right to buy) · Derivative	150,000	$0.00 Strike: $22.07	$0.00	Disclosure SEC source: 0001209191-21-006700 · doc4.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 150,000 shares Expires 2031-01-31 F1 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024 Read SEC document
January 31, 2021 Filed May 21, 2021 17:44 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-034823 · doc4.xml · derivative · entry 6 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2020 representing 15,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2021. F4 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2020 representing 15,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2021. Read SEC document
January 31, 2021 Filed May 21, 2021 17:44 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-034823 · doc4.xml · nonDerivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
January 03, 2021 Filed May 21, 2021 17:44 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	8,807	$0.00	$0.00	Disclosure SEC source: 0001209191-21-034823 · doc4.xml · derivative · entry 5 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,689 Underlying: Ordinary Shares · 8,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. 33.33% of the RSUs vested in equal monthly installments through January 3, 2021. The remaining 33.33% of the RSUs will vest on January 3, 2022. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. 33.33% of the RSUs vested in equal monthly installments through January 3, 2021. The remaining 33.33% of the RSUs will vest on January 3, 2022. Read SEC document
January 03, 2021 Filed May 21, 2021 17:44 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	8,807	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-034823 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
December 14, 2020 Filed Dec 15, 2020 22:27 UTC	UroGen Pharma Ltd. URGN · Entity 4466	PurchaseOrdinary Shares	10,000	$18.50	$185,000.00	Disclosure SEC source: 0001209191-20-063558 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,117 Read SEC document
December 04, 2020 Filed Dec 4, 2020 21:35 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	61,652	$0.00	$0.00	Disclosure SEC source: 0001209191-20-061812 · doc4.xml · derivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,496 Underlying: Ordinary Shares · 61,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. The remaining unvested restricted stock units will vest at a rate of 2.778% in equal monthly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. The remaining unvested restricted stock units will vest at a rate of 2.778% in equal monthly installments thereafter. Read SEC document
December 04, 2020 Filed Dec 4, 2020 21:35 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	61,652	$0.00	$0.00	Disclosure SEC source: 0001209191-20-061812 · doc4.xml · nonDerivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of restricted stock units that vested from June 3, 2020 through December 3, 2020 through the issuance of ordinary shares. Read SEC document
December 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	8,808	$0.00	$0.00	Disclosure SEC source: 0001209191-21-046344 · doc4a.xml · derivative · entry 14 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,496 Underlying: Ordinary Shares · 8,808 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document
December 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	8,808	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-046344 · doc4a.xml · nonDerivative · entry 7 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
November 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	8,808	$0.00	$0.00	Disclosure SEC source: 0001209191-21-046344 · doc4a.xml · derivative · entry 13 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,304 Underlying: Ordinary Shares · 8,808 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document
November 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	8,808	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-046344 · doc4a.xml · nonDerivative · entry 6 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
October 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	8,808	$0.00	$0.00	Disclosure SEC source: 0001209191-21-046344 · doc4a.xml · derivative · entry 12 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,112 Underlying: Ordinary Shares · 8,808 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document
October 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	8,808	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-046344 · doc4a.xml · nonDerivative · entry 5 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
September 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	8,807	$0.00	$0.00	Disclosure SEC source: 0001209191-21-046344 · doc4a.xml · derivative · entry 11 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,920 Underlying: Ordinary Shares · 8,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document
September 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	8,807	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-046344 · doc4a.xml · nonDerivative · entry 4 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
August 03, 2020 Filed Jul 12, 2021 22:59 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Units · Derivative	8,807	$0.00	$0.00	Disclosure SEC source: 0001209191-21-046344 · doc4a.xml · derivative · entry 10 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,727 Underlying: Ordinary Shares · 8,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · date: On December 4, 2020, the reporting person filed a Form 4 that inadvertently reported that a total of 61,652 shares vested on May 3, 2020. In fact, the shares vested monthly from June 3, 2020. F3 · derivative.exercise_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. F3 · derivative.expiration_date: On January 3, 2019, the reporting person was granted restricted stock units ("RSUs") representing 317,065 ordinary shares. 1/3rd of the RSUs vested on January 3, 2020, with the balance vesting in equal monthly installments thereafter over a period of three years. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.